European Commission

Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

Friday, October 15, 2021 - 9:11pm

Phase 3 clinical data and real-world data both demonstrated the Johnson & Johnson single-shot COVID-19 vaccine was strong and long-lasting.

Key Points: 
  • Phase 3 clinical data and real-world data both demonstrated the Johnson & Johnson single-shot COVID-19 vaccine was strong and long-lasting.
  • "Johnson & Johnson is steadfast in its commitment to protect as many people globally as possible against the continued spread of COVID-19," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson.
  • You should not get the Janssen COVID-19 Vaccine if you:
    had a severe allergic reaction to any ingredient of this vaccine.
  • You should seek medical attention right away if you have any of the following symptoms after receiving Janssen COVID-19 Vaccine:

Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer

Friday, October 15, 2021 - 1:00pm

TNBC is the most aggressive type of breast cancer and accounts for approximately 15% of all breast cancers.

Key Points: 
  • TNBC is the most aggressive type of breast cancer and accounts for approximately 15% of all breast cancers.
  • Patients were randomly allocated to receive either sacituzumab govitecan or a chemotherapy chosen by the patients treating physician.
  • TNBC is the most aggressive type of breast cancer and accounts for approximately 15% of all breast cancers.
  • Among women with metastatic TNBC, the five-year survival rate is 12%, compared with 28% for those with other types of metastatic breast cancer.

Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Two Different Types of Cancer

Friday, October 15, 2021 - 12:20pm

The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.

Key Points: 
  • The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.
  • KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
  • KEYTRUDA, in combination with LENVIMA, is indicated for the first-line treatment of adult patients with advanced RCC.
  • The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.

Announcing the 2021 .eu Web Awards Winners!

Friday, October 15, 2021 - 8:00am

Last night the 2021 .eu Web Awards ended in epic fashion at the Teatro Antico in Taormina, Italy.

Key Points: 
  • Last night the 2021 .eu Web Awards ended in epic fashion at the Teatro Antico in Taormina, Italy.
  • Hosted by EURid , the .eu Web Awards are a competition for the best .eu, .
  • After last years virtual only event, we were pleased to once again celebrate the finalists and winners in person.
  • This is what the Web Awards is all about, bringing together people from various industries and backgrounds and honouring them for having chosen a .eu for their online presence.

iThera Medical awarded major European grant to translate its optoacoustic imaging technology from research to routine clinical use

Friday, October 15, 2021 - 5:00am

Multispectral optoacoustic tomography (MSOT), developed by iThera Medical, is an innovative, non-invasive diagnostic imaging method that has the potential to provide diagnostic breakthroughs in a range of diseases.

Key Points: 
  • Multispectral optoacoustic tomography (MSOT), developed by iThera Medical, is an innovative, non-invasive diagnostic imaging method that has the potential to provide diagnostic breakthroughs in a range of diseases.
  • MSOT uses a physical effect that no other clinical imaging technology has used before: the conversion of light energy into sound waves, also known as the photoacoustic effect.
  • MSOT has already demonstrated its clinical value through numerous pilot studies in a wide variety of disease areas.
  • Since its incorporation in 2010, iThera Medical develops and markets optoacoustic imaging systems for preclinical and clinical research.

OneProjects Announces $17 Million in New Financing to Advance Development of 4D Cardiac Imaging Technology

Thursday, October 14, 2021 - 12:30pm

OneProjects, developer of four-dimensional (4D) cardiac imaging technology, today announced a total of $17 million in new financing for the company, including an $8 million Series A2 financing and two grants worth $9 million.

Key Points: 
  • OneProjects, developer of four-dimensional (4D) cardiac imaging technology, today announced a total of $17 million in new financing for the company, including an $8 million Series A2 financing and two grants worth $9 million.
  • The grants were awarded by the Irish governments Disruptive Technologies Innovation Fund ($6 million) and the EIC Accelerator ($3 million).
  • The company will use the new funds to complete product development, conduct clinical trials, gain FDA clearance and prepare for U.S. commercialization of the first product developed from its proprietary 4D cardiac imaging platform, VERAFEYE.
  • This technology is designed to improve the treatment of atrial fibrillation and other cardiac arrhythmias, and can also be applied to benefit structural heart procedures.

Fourth TCFD Status Report Highlights Greatest Progress to Date on TCFD Adoption

Thursday, October 14, 2021 - 12:09pm

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- The Task Force on Climate-related Financial Disclosures (TCFD), established by the Financial Stability Board (FSB), published its 2021 Status Report today.

Key Points: 
  • NEW YORK, Oct. 14, 2021 /PRNewswire/ -- The Task Force on Climate-related Financial Disclosures (TCFD), established by the Financial Stability Board (FSB), published its 2021 Status Report today.
  • Since last year's report, the number of TCFD supporters has grown by over a third more than 1,000 new organizations now support the TCFD recommendations, bringing the total to over 2,600 globally.
  • For the first time, the Task Force released updates to the implementation guidance (Annex) initially published in 2017 with the TCFD Recommendations Report.
  • The full 2021 Status Report, updated Annex, and guidance document are available on the TCFD website .

TECO 2030 Signs Supply Frame Agreement with Chemgas Shipping

Thursday, October 14, 2021 - 10:02am

LYSAKER, NORWAY / ACCESSWIRE / October 14, 2021 / Norwegian maritime cleantech company TECO 2030 ASA (OTCQB:TECFF) has signed a supply frame agreement with the Dutch shipowner Chemgas Shipping BV.

Key Points: 
  • LYSAKER, NORWAY / ACCESSWIRE / October 14, 2021 / Norwegian maritime cleantech company TECO 2030 ASA (OTCQB:TECFF) has signed a supply frame agreement with the Dutch shipowner Chemgas Shipping BV.
  • Chemgas Shipping plans to install fuel cell modules from TECO 2030 on up to 120 transport barges and between 40-60 tugboats.
  • "We are thrilled that Chemgas Shipping has chosen to cooperate with TECO 2030 on this ambitious and important project, and that we have now been able to progress from a letter of intent to a supply frame agreement," says Tore Enger, CEO of TECO 2030 ASA.
  • "The economic potential of this framework agreement is large for TECO 2030 and may lead to revenues of up to 150 million Euros over the next three to eight years," Enger adds.

Cantargia receives positive EMA opinion for orphan designation of nadunolimab for treatment of pancreatic cancer

Thursday, October 14, 2021 - 7:43am

STOCKHOLM, Oct. 14, 2021 /PRNewswire/ -- Cantargia AB today announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has issued a positive opinion for orphan designation of nadunolimab (CAN04) for treatment of pancreatic cancer.

Key Points: 
  • STOCKHOLM, Oct. 14, 2021 /PRNewswire/ -- Cantargia AB today announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has issued a positive opinion for orphan designation of nadunolimab (CAN04) for treatment of pancreatic cancer.
  • The COMP at the EMA has issued a positive opinion for orphan designation of CAN04 for treatment of pancreatic cancer.
  • The opinion is forwarded to the European Commission which is expected to grant the orphan designation within 30 days.
  • CAN04 was granted US Orphan Drug Designation for treatment of pancreatic cancer by the Food and Drug Administration (FDA) in September 2021.

Demystifying AI for AML: European Banking Federation and SAS help banks worldwide fight financial crime

Wednesday, October 13, 2021 - 5:12pm

The European Banking Federation (EBF) uniting 32 national banking associations in Europe, representing 5,981 banks with roughly 2.6 million employees has partnered with SAS to help financial firms worldwide curb the deluge.

Key Points: 
  • The European Banking Federation (EBF) uniting 32 national banking associations in Europe, representing 5,981 banks with roughly 2.6 million employees has partnered with SAS to help financial firms worldwide curb the deluge.
  • The AML Masterclass will explore how AI and machine learning technology can help boost banks' AML compliance efforts.
  • We are confident that this collaboration with SAS will help us prepare our members, and the broader banking community, for this new reality."
  • The European Banking Federation is the voice of the European banking sector, bringing together national banking associations from across Europe.